Astellas, Seagen and Merck Report P-Ib/II (EV-103/KEYNOTE-869) Cohort K Trial Results of Padcev (enfortumab vedotin-ejfv) as 1L Treatment of Advanced Urothelial Cancer
Shots:
- The P-Ib/II (EV-103/KEYNOTE-869) cohort K trial evaluating Padcev + Keytruda vs Padcev alone in a ratio (1:1) in 457 patients with unresectable LA or mUC
- The results from the combination therapy & monothx. arms showed ORR (64.5% & 45.2%), CR (10.5% & 4.1%), PR (53.9% & 41.1%), m-DoR (not reached & 13.2mos.). In the combination therapy, the results were consistent with prior reported results of (EV-103/KEYNOTE-869) dose escalation cohort & expansion cohort A. The results were presented at ESMO 2022
- The results from the 2EPs in combination therapy & monothx. arms, m-PFS (not reached & 8.0mos.), m-OS (22.3mos. & 21.7mos.), TRAEs of any grade (≥20%). Enfortumab Vedotin + pembrolizumab is being studied in multiple P-III studies for LA/mUC & MIBC
Ref: Astellas | Image: Astellas
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
